Company Overview
| Stock Name | HBM Holdings-B |
|---|---|
| Stock Code | 02142 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 臨床階段生物製藥公司,從事研究及開發免疫與腫瘤疾病領域的差異化抗體療法,擁有多元化候選藥物管線及和鉑抗體平台。 |
| Listing Date | 2020-12-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中国上海市徐匯區楓林路420號楓林國際大廈二期A座12樓 |
| Business Address (Hong Kong) | 香港皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | harbourbiomed.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 12.38 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 12,380 |
| Par Value | To be extracted |
| Offer Period | 2020-11-30 to 2020-12-03 |
| Global Offering Shares | 138,221,000 shares |
| HK Public Offer Shares (Initial) | 13,824,000 shares (10.0%) |
| Public Offer Lots (Initial) | 13,824lots (Pool A6,912lots,Pool B6,912lots) |
| International Placing Shares (Initial) | 124,397,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 767,891,160 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 41.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,711,175,980 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 12,380 |
| 2 lots | 2,000 | HK$ 24,760 |
| 3 lots | 3,000 | HK$ 37,140 |
| 4 lots | 4,000 | HK$ 49,520 |
| 5 lots | 5,000 | HK$ 61,900 |
| 6 lots | 6,000 | HK$ 74,280 |
| 7 lots | 7,000 | HK$ 86,660 |
| 8 lots | 8,000 | HK$ 99,040 |
| 9 lots | 9,000 | HK$ 111,420 |
| 10 lots | 10,000 | HK$ 123,800 |
| 15 lots | 15,000 | HK$ 185,700 |
| 20 lots | 20,000 | HK$ 247,600 |
| 25 lots | 25,000 | HK$ 309,500 |
| 30 lots | 30,000 | HK$ 371,400 |
| 35 lots | 35,000 | HK$ 433,300 |
| 40 lots | 40,000 | HK$ 495,200 |
| 45 lots | 45,000 | HK$ 557,100 |
| 50 lots | 50,000 | HK$ 619,000 |
| 60 lots | 60,000 | HK$ 742,800 |
| 70 lots | 70,000 | HK$ 866,600 |
| 80 lots | 80,000 | HK$ 990,400 |
| 90 lots | 90,000 | HK$ 1,114,200 |
| 100 lots | 100,000 | HK$ 1,238,000 |
| 200 lots | 200,000 | HK$ 2,476,000 |
| 300 lots | 300,000 | HK$ 3,714,000 |
| 400 lots | 400,000 | HK$ 4,952,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 500 lots | 500,000 | HK$ 6,190,000 |
| 600 lots | 600,000 | HK$ 7,428,000 |
| 700 lots | 700,000 | HK$ 8,666,000 |
| 800 lots | 800,000 | HK$ 9,904,000 |
| 900 lots | 900,000 | HK$ 11,142,000 |
| 1,000 lots | 1,000,000 | HK$ 12,380,000 |
| 2,000 lots | 2,000,000 | HK$ 24,760,000 |
| 3,000 lots | 3,000,000 | HK$ 37,140,000 |
| 4,000 lots | 4,000,000 | HK$ 49,520,000 |
| 5,000 lots | 5,000,000 | HK$ 61,900,000 |
| 6,000 lots | 6,000,000 | HK$ 74,280,000 |
| 6,912 lots | 6,912,000 | HK$ 85,570,560 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 10.54B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 9,506,492,560 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 亏损约67.5百万美元 |
| Period-End Cash Balance | 33.4百万美元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | 超過300百萬美元 |
Financial Data
Unit:
'000
USD
Income Statement
| Item | 2018 | 2019 |
|---|---|---|
| Revenue | 1,483 | 9,070 |
| Cost of sales | -905 | -957 |
| Gross profit | 916 | 9,113 |
| Other income and gains, net | 926 | 953 |
| Administrative expenses | -7,316 | -8,037 |
| Net finance costs | -902 | -972 |
| Profit before tax | -7,626 | -9,226 |
| Income tax expense | -715 | -721 |
| Profit for the year | -7,246 | -7,276 |
| Profit attributable to owners | -7,226 | -7,126 |
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 11.02 |
|---|---|
| First Day Open | HK$ 11.94 |
| First Day Change | -10.99% |
| First Day Volume | 57898000.0 |
| First Day Turnover | 695749000.0 |
| Use of Proceeds | 1、約591.5百萬港元(占37%)預期將用于撥資我們的核心產品;
2、約367.7百萬港元(占23%)預期將用于撥資我們的支柱資產HBM4003在大中華區及澳洲的進行中及計劃進行的臨床試驗、籌備在大中華區、美國及其他司法權區的注冊備案及潛在商業化推出;
3、約239.8百萬港元(占15%)預期將用于撥資我們其他正在尋求IND批準及尚未開始臨床試驗或臨床前研究的候選藥物的研發;
4、約191.9百萬港元(占12%)預期將用于撥資和鉑抗體平臺產生的創新型分子發現;
5、約79.9百萬港元(占5%)預期將用于撥資持續改進平臺技術、利用和鉑抗體平臺尋求授權及合作機會;
6、約127.9百萬港元(占8%)預期將用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (5)
Joint Bookrunners (7)
Joint Lead Managers (5)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 3W Funds | 38,761,780 HKD | — | 2.27% | — | 6 months | 2021-06-10 |
| 2 | Anlan Funds | 54,261,540 HKD | — | 3.17% | — | 6 months | 2021-06-10 |
| 3 | BlackRock Funds | 232,595,440 HKD | — | 13.59% | — | 6 months | 2021-06-10 |
| 4 | HBM Healthcare Investments (Cayman) Ltd. | 77,523,560 HKD | — | 4.53% | — | 6 months | 2021-06-10 |
| 5 | Hillhouse Funds | 77,523,560 HKD | — | 4.53% | — | 6 months | 2021-06-10 |
| 6 | Hudson Bay Master Fund LTD | 77,523,560 HKD | — | 4.53% | — | 6 months | 2021-06-10 |
| 7 | LC HEALTHCARE FUND I, L.P. | 38,761,780 HKD | — | 2.27% | — | 6 months | 2021-06-10 |
| 8 | Octagon Investments Master Fund LP | 77,523,560 HKD | — | 4.53% | — | 6 months | 2021-06-10 |
| 9 | OrbiMed Funds | 38,761,780 HKD | — | 2.27% | — | 6 months | 2021-06-10 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 王勁松 | — |
| Company Secretary | 呂穎一 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 永豐利投資有限公司持股12.18%,LC Healthcare Fund I, L.P.持股8.53%,HARBOURBIO LLC持股7.86%,王勁松持股7.86%,Owap Investment Pte Ltd.持股6.59% |
|---|




